← boardnext 2027-12
ANVS
Annovis Bio Inc.distress 8/10 · high distress / dilution risk$1.72-1%today-66% from 52w high
Lead: Alzheimer's disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$14M
Runway
0.5 yrs
Shares 1y
+78%
Price & events
-44.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-1.4%
1W
-1.4%
1M
-5.2%
3M
-43.0%
6M
-35.5%
1Y
-83.9%
2Y
-98.6%
5Y
-79.0%
All
Overview
- Market Cap
- $59.42M
- Volume
- 29.50K
- 52 Week Range
- $1.59 – $5.10
- Total Shares
- 34.65M
- Float Shares
- 30.67M
- Short %
- 12.55%
- % Held by Insiders
- 8.26%
- % Held by Institutions
- 16.70%
- RVOL
- 0.03x
- Beta
- 1.19
Pipeline stages · 1 programs
buntanetap/posiphen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 3 | buntanetap/posiphen | Early Alzheimers Disease | — | active not recruiting |
| 2029-09 Estimated 50% readout ~2029-11-15 | Phase 2/3 | buntanetap/posiphen | Parkinson's Disease (PD), Deep Brain Stimulation | — | recruiting |
Catalyst news & presentations · 4
- early 2028Guided 40%readoutPhase 3buntanetap · Disease-modifying efficacy readoutSEC 8-K
- early 2027Guided 40%readoutPhase 3buntanetap · First symptomatic efficacy readoutSEC 8-K
- early next yeartrial initiationsecondaryPhase 3buntanetap · Plan to initiate pivotal Phase 3 trials in early ADSEC 8-K
- 2024-10-10fda agreementbuntanetap · FDA granted clearance to proceed with Phase 3 studies and aligned on NDA pathSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+541% upside) · 3 analysts
- 2026-07-08Roth CapitalBuy
- 2026-04-14Canaccord GenuityBuy
- 2025-09-30Canaccord GenuityBuy
- 2025-09-03HC Wainwright & Co.Buy
- 2025-06-09HC Wainwright & Co.Buy
- 2025-05-15Canaccord GenuityBuy
Competitors — Alzheimer's disease
- GSKGSK plc$217.0B · D1
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- ACADACADIA PHARMACEUTICALS INC$4.2B · D0
- DNLIDenali Therapeutics Inc.$3.6B · D2
- NAMSNewAmsterdam Pharma Co N.V.$3.6B · D0
- MPLTMapLight Therapeutics, Inc.$1.5B · D2
- NMRANeumora Therapeutics, Inc.$281M · D5
- PMNProMIS Neurosciences Inc.$125M · D5
- INMBInmune Bio, Inc.$47M · D5
Recent news
- 2026-07-12Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial - MyChesCo
- 2026-07-10Annovis Bio Completes Enrollment for Pivotal Phase 3 Alzheimer’s Trial, Plans NDA Submissions in 2027 and 2028 12 - Minichart
- 2026-07-10Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial - TipRanks
- 2026-07-07Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
- 2026-07-07Annovis Bio completes enrollment in phase 3 Alzheimer’s trial By Investing.com - Investing.com Nigeria
- 2026-07-07Annovis enrolls 850 patients in Phase 3 Alzheimer’s study - Stock Titan
- 2026-07-01Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones - citybiz
- 2026-07-01Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - The Manila Times
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.